AKTX

$9.29+13.98%visit website

Akari Therapeutics Plc

Market Cap

$1.45T

Live price × SEC shares (Aug 13, 2026)

Sector

Health Care

Industry

Biotechnology

Beta (raw)

1.46

60mo monthly vs SPY

P/E (TTM)

N/M

TTM to Jun 2026 · negative earnings

P/S (TTM)

—

Mkt cap / TTM revenue

P/B

77816.4

Mkt cap / shareholders' equity

EV/EBITDA (TTM)

—

EV / TTM EBITDA

Loading…

Financial Statements

USD thousands	Q3 FY2025 Sep 30, 2025	Q4 FY2025 Dec 31, 2025	Q1 FY2026 Mar 31, 2026	Q2 FY2026 Jun 30, 2026	TTM Jun 30, 2026
Research & development	249	1,086	1,459	2,077	4,871
Selling, general & administrative	1,975	2,141	2,169	2,525	8,810
Total operating expenses			15,758
Operating income	(7,404)	(3,227)	(15,758)	(4,602)	(30,991)
Interest expense	121	723	61	80	985
Pretax income	(7,488)	(5,213)	(15,314)	(4,807)	(32,822)
Income tax	(1,088)	85	(859)	0	(1,862)
Net income	(6,400)	(5,298)	(14,455)	(4,807)	(30,960)
EPS (basic) ($)	0.00		0.00	0.00	—
EPS (diluted) ($)	0.00		0.00	0.00	—
Weighted avg. shares (basic)	65,326,237		118,757,013	143,317,469
Weighted avg. shares (diluted)	65,326,237		118,757,013	143,317,469

Source: SEC XBRL filings (10-K, 10-Q). Per-share data in dollars; shares in thousands. Latest: 10-Q filed Aug 13, 2026, period ended Jun 30, 2026. flagged for review— withheld, failed a consistency check restated or split-adjustedhover a value for its source

Showing the last 5 quarters. 19 more quarters, back to Mar 2014, with Tormere Pro.